Source: Zealand Pharma A/S and reported by http://globenewswire.com/
Copenhagen, 2 June 2015 – Zealand Pharma A/S (“Zealand”) (NASDAQ Copenhagen: ZEAL) informs that new data will be presented on lixisenatide, the company’s first own-invented marketed medicine for the treatment of Type 2 diabetes, at the upcoming 75th Scientific Sessions of the American Diabetes Association (ADA) to be held in Boston on 5 – 9 June 2015. Further, at the event, Zealand will present two of its novel preclinical peptide therapeutics with potential for better treatment of diabetes and obesity.
Lixisenatide
Lixisenatide is marketed worldwide ex-US as Lyxumia® by Sanofi (SANF.PA) under a global license agreement. Lixisenatide is the first once-daily short-acting GLP-1 receptor agonist with a pronounced effect on prandial (meal-related) glucose and its therapeutic profile will be featured in a total of 13 presentations at ADA. These include important results of the cardiovascular safety outcome trial, ELIXA, to be unveiled in a symposium under the title:
“The Evaluation of Lixisenatide in Acute Coronary Syndrome —The Results of ELIXA”,
- See more at: http://globenewswire.com/news-release/2015/06/02/741240/0/en/New-data-on-lixisenatide-Lyxumia-including-ELIXA-results-on-LixiLan-and-on-novel-Zealand-peptide-therapeutics-to-be-presented-at-the-American-Diabetes-Association-s-ADA-75th-Scient.html#sthash.ncKCumSq.dpuf